Skip to main content

Advertisement

Table 4 Comparative evaluation between the EMBRACE and the ERIBEX studies

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

  EMBRACE ERIBEX
Population
 Patients (n) 503 (EM) 258
 Age (years) 55 59
 Triple-negative tumour (%) 18 22.5
 HER2+ tumour (%) 16 10.2
 Prior hormonal therapy (%) 85 76.7
 Prior anthracycline or taxane treatment (%) 99 100
 Prior capecitabine treatment (%) 73 90.7
 Median prior metastatic chemotherapies; n (range) 4 (1–7) 4 (1–9)
Metastatic sites
 Bone (%) 61 68.2
 Liver (%) 60 67.4
 Node (%) 44 45.7
 Lung (%) 38 38
Chemotherapy
 Median number of EM cycles (range) 5 (1–23) 5 (1–19)
Efficacy
 Median overall survival (month, 95 %CI) 13.1 11.2 (9.3–12.12
 Median progression-free survival (month, 95 %CI) 3.7 3.8 (3.2–4.2)
 Overall response rate (%) 12 26
 Clinical benefit rate 23 36
Safety
 Side effects (grade 1–4, %) 99 94.2
Side effects most commonly encountered
 Asthenia (%) 54 60.9
 Neutropenia (%) 52 38.4
 Peripheral Neuropathies (%) 35 43
 Nausea (%) 35 10.5
 Alopecia (%) 45 19.4
Grade 3 toxicity (%) 36.2 39.5
Grade 4 toxicity (%) 27.2 17
 Grade 3–4 neutropenia 21 %/24 % 20.9 % grade 3–4
 Grade 3-/4 peripheral neuropathy 8 %/<1 % 3.9 % grade 3–4
Treatment discontinuation due to toxicity (%) 13 13.1